---
title: "DTIL.US (DTIL.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DTIL.US/news.md"
symbol: "DTIL.US"
name: "DTIL.US"
parent: "https://longbridge.com/en/quote/DTIL.US.md"
datetime: "2026-05-20T20:37:24.650Z"
locales:
  - [en](https://longbridge.com/en/quote/DTIL.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DTIL.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DTIL.US/news.md)
---

# DTIL.US (DTIL.US) — Related News

### [iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting | DTIL Stock News](https://longbridge.com/en/news/286241652.md)
*2026-05-13T02:00:00.000Z*
> iECURE, Inc. presented preliminary clinical data at the ASGCT Annual Meeting regarding its ongoing OTC-HOPE trial for EC

### [De-Extinct Dire Wolves Ready To Breed; Bioscience Company Pushes Forward Multiple Projects](https://longbridge.com/en/news/285816836.md)
*2026-05-09T15:42:20.000Z*
> Colossal Biosciences has announced that its de-extinct dire wolves, Romulus, Remus, and Khaleesi, are now breeding-aged,

### [Alpenglow Biosciences Introduces Summit AI for Quantitative Analysis of Whole Tissue Imaging in Dermatology](https://longbridge.com/en/news/285236292.md)
*2026-05-05T15:43:20.000Z*
> Alpenglow Biosciences has launched Summit AI, a multimodal AI platform for quantitative analysis of whole tissue imaging

### [Precision Biosciences | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 10.84 M](https://longbridge.com/en/news/285195959.md)
*2026-05-05T11:22:03.000Z*
### [Precision Biosciences | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 10.84 M](https://longbridge.com/en/news/285195892.md)
*2026-05-05T11:21:23.000Z*
### [07:00 ETAltesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations](https://longbridge.com/en/news/285191627.md)
*2026-05-05T11:00:40.000Z*
> Altesa BioSciences has enrolled its first patient in the Phase 2b CARDINAL clinical trial, evaluating vapendavir as a tr

### [Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update | DTIL Stock News](https://longbridge.com/en/news/285192804.md)
*2026-05-05T03:01:00.000Z*
> Precision BioSciences reported its Q1 2026 financial results, highlighting advancements in its clinical trials for PBGEN